Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimexolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.61 |
| ▸ | AR | P10275 | 2/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL6 | P05231 | 1/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.61 |
| ▸ | GLUL | P15104 | 1/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimexolone SCHEMBL3062722 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL29030108 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL29030109 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL445300 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL13693339 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL19327140 | 0.94 | NR3C1 (0.88) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9470879 | 0.92 | NR3C1 (0.86) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9470890 | 0.92 | NR3C1 (0.86) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9467046 | 0.91 | NR3C1 (0.84) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9467031 | 0.91 | NR3C1 (0.84) | NR3C1PGRHIF1ALMNANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022103250-A1 | SYNERGISTIC OPHTHALMOLOGICAL COMPOSITION IN A LOW-CONCENTRATION DOSE THAT IS EFFECTIVE IN THE PREVENTION, CONTROL AND ERADICATION OF PRESBYOPIA | SANCHEZ GALEANA CESAR ALEJANDRO (MX) | 2022-05-19 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20080275015-A1 | Formulation and Method for Treating Interstitial Cystitis and Related Bladder Conditions | POTTER JEFFREY A | 2008-11-06 | — | — | US | disclosed |
| US-20080275015-A1 | Formulation and Method for Treating Interstitial Cystitis and Related Bladder Conditions | POTTER JEFFREY A | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275015-A1 | Formulation and Method for Treating Interstitial Cystitis and Related Bladder Conditions | MMP1, CYSLTR2, CYSLTR1 | NR3C1 4236/4885PGR 3812/4885HIF1A 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.